Screener
Gyre Therapeutics, Inc. GYRE Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Six Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|---|
| Proceeds from the issuance of common stock in ATM program | — | 509 | |
| Net cash provided by financing activities | 13 | 21,589 | |
| Effect of exchange rate changes on cash | 928 | 10 | |
| Net (decrease) increase in cash | (5,905) | 17,317 | |
| Cash at beginning of the period | 49,192 | 39,048 | |
| Cash at end of period | $ | $$43,287 | 56,365 |
| Supplement disclosure of non-cash operating activities: | |||
| Right-of-use asset obtained in exchange for operating lease liabilities | — | 1,602 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s net change in cash?
- Gyre Therapeutics, Inc. (GYRE) reported net change in cash of -$6.34M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s net change in cash changed year-over-year?
- Gyre Therapeutics, Inc.'s net change in cash decreased by 145.0% year-over-year, from $14.09M to -$6.34M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Gyre Therapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude